Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE's iSTRYM digital therapeutics platform is the first-mover in the industry.
Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE's iSTRYM digital therapeutics platform is the first-mover in the industry.
MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
As MINDCURE's iSTRYM digital therapeutics platform rapidly gathers momentum, the company looks poised to join the emerging rally in the sector.
Mind Cure Health Inc., is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology.
MINDCURE announces an LOI with Awaken Life Sciences for the deployment of MINDCURE's iSTRYM digital therapeutics platform in Awaken's addiction treatment clinics.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now